A marketing authorization lets you sell. AMNOG decides what Germany will pay — and for most launches, it sets the ceiling on revenue before the sales force ever gets going. Here's how the process actually works.
A new patented medicine launches in Germany at a free price, then goes through AMNOG: you file a benefit dossier, the IQWiG rates its added benefit against a defined comparator, the G-BA issues a resolution, and the statutory insurers (GKV-Spitzenverband) negotiate a reimbursement price (Erstattungsbetrag). Demonstrated added benefit buys pricing room; none usually means a reference-price ceiling. This single process — not your home-market price — sets what Germany pays.
AMNOG — the Arzneimittelmarktneuordnungsgesetz, in force since 2011 — is the German system for assessing the benefit of new patented medicines and setting their reimbursed price.
Before AMNOG, manufacturers set prices freely and the statutory system largely paid them. AMNOG changed that: a new drug still launches at a free price, but from then on its price has to be justified by evidence of added benefit over the existing standard of care. The result is not a yes/no market-access gate — the drug is reimbursable throughout — but a price gate that shapes the entire commercial case.
Getting authorized and getting a price are two different projects. AMNOG is the second one.
From launch to a binding reimbursement price is roughly a year. The clock and the comparator are fixed early; the evidence you bring decides the outcome.
On market entry you set the price yourself. This window is short — and since the 2023 reform the negotiated price applies retroactively from month 7, so the free-price period is a revenue lever, not a lasting one.
Within the required window you submit a dossier to the G-BA (Federal Joint Committee) documenting the drug's added benefit against the comparator.
The IQWiG evaluates the evidence and rates the added benefit (Zusatznutzen) versus the zweckmaessige Vergleichstherapie — the appropriate comparator. This is where most of the value is won or lost.
The G-BA issues a formal resolution on the added-benefit category (see below). It also defines the patient subpopulations to which each rating applies.
The GKV-Spitzenverband negotiates the reimbursement amount (Erstattungsbetrag). No agreement within the deadline goes to an arbitration board (Schiedsstelle). The outcome then forks:
The IQWiG assessment and the G-BA resolution place the drug into one of six categories — and the rating is made separately for each patient subpopulation, so one drug can hold different ratings at once.
The negotiation is anchored to these ratings, the annual cost of the comparator, and prices for the same drug in a basket of European countries. A strong rating in a large subpopulation is worth far more than a strong rating in a niche one — which is why the target population defined in the dossier is a strategic choice, not a formality.
The GKV-Finanzstabilisierungsgesetz (GKV-FinStG) tightened AMNOG to control statutory spending. If your last German data is older, these are the shifts that matter most:
Thresholds and rules are reformed periodically. Treat specific figures as indicative and confirm the current position for your product before you plan around them.
In Germany, market access is structure before visibility. The reimbursement case should be built into the plan from day one — not bolted on at launch.
In a focused session we map your realistic added-benefit scenario, the likely comparator, and the commercial model that fits — before you commit budget. We own the market-access read and orchestrate the dossier with specialist partners.